Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 229

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

Open access
Tarek, Nidale, Le Luduec, Jean-Benoit, Gallagher, Meighan M., Zheng, Junting, Venstrom, Jeffrey M., Chamberlain, Elizabeth, Modak, Shakeel, Heller, Glenn, Dupont, Bo, Cheung, Nai-Kong V., Hsu, Katharine C.·2012·Journal of Clinical Investigation

Abstract

Survival outcomes for patients with high-risk neuroblastoma (NB) have significantly improved with anti-disialoganglioside GD2 mAb therapy, which promotes NK cell activation through antibody-dependent cell-mediated cytotoxicity. NK cell activation requires an interaction between inhibitory killer cell immunoglobulin-like receptors (KIRs) and HLA class I ligands. NK cells lacking KIRs that are specific for self HLA are therefore "unlicensed" and hyporesponsive. mAb-treated NB patients lacking HLA class I ligands for their inhibitory KIRs have significantly higher survival rates, suggesting that NK cells expressing KIRs for non-self HLA are mediating tumor control in these individuals. We found that, in the presence of mAb, both licensed and unlicensed NK cells are highly activated in vitro. However, HLA class I expression on NB cell lines selectively inhibited licensed NK cell activity, permitting primarily unlicensed NK cells to mediate antibody-dependent cell-mediated cytotoxicity. These results indicate that unlicensed NK cells play a key antitumor role in patients undergoing mAb therapy via antibody-dependent cell-mediated cytotoxicity, thus explaining the potent "missing KIR ligand" benefit in patients with NB.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci62749

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 229

Metadata

Authors
Tarek, N., Le Luduec, J.-B., Gallagher, M. M., Zheng, J., Venstrom, J. M., Chamberlain, E., Modak, S., Heller, G., Dupont, B., Cheung, N.-K. V., & Hsu, K. C.
Venue
Journal of Clinical Investigation
Published
2012-09-04
Volume
122
Issue
9
Pages
3260-3270
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2067590368
Cited by
229
References
5
FWCI
8.63
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. https://app.cochat.ai/papers/10.1172/jci62749
The paper
Tarek, N., Le Luduec, J.-B., Gallagher, M. M., Zheng, J., Venstrom, J. M., Chamberlain, E., Modak, S., Heller, G., Dupont, B., Cheung, N.-K. V., & Hsu, K. C. (2012). Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. Journal of Clinical Investigation. https://doi.org/10.1172/jci62749

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.